Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 13.8%

Shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) traded up 13.8% during mid-day trading on Friday . The stock traded as high as $1.34 and last traded at $1.32. 50,846 shares were traded during mid-day trading, a decline of 73% from the average session volume of 185,626 shares. The stock had previously closed at $1.16.

Alaunos Therapeutics Stock Performance

The firm has a market cap of $21.13 million, a P/E ratio of -0.55 and a beta of -0.33. The business’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.57.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. Magnolia Capital Advisors LLC bought a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 432,969 shares of the company’s stock, valued at approximately $56,000. Magnolia Capital Advisors LLC owned about 0.18% of Alaunos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 27.72% of the company’s stock.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine.